Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 6:34 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 2,287 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fasted State Clear all

Conditions: Advanced Solid Tumor
Interventions: Pimasertib, Temsirolimus; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: Los Angeles, California • Rockland, Massachusetts • Houston, Texas

Conditions: Aging, Metabolism
Interventions: Intermittent Fasting, 400 IU Vitamin E, 1000 mg Vitamin C; Other · Dietary Supplement
Lead sponsor: University of Florida; Other
Eligibility: 19 Years to 30 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Breast Cancer
Interventions: exemestane; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Metastatic Breast Cancer
Interventions: Lapatinib and RAD-001; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: ACL, Opioid Use, Cryotherapy Effect, Vibration; Exposure, Pain, Postoperative
Interventions: VibraCool mechanical stimulation and neuromodulatory therapeutic device, Cryocompression (Game Ready, Bregs) device, Standard ice packs; Device
Lead sponsor: Columbia University; Other
Eligibility: Not listed
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes Mellitus
Interventions: IDegLira, Insulin Degludec (U-100), Insulin Aspart; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Pain
Interventions: Naproxen sodium and diphenhydramine hydrochloride soft capsules, Naproxen sodium and diphenhydramine hydrochloride coated tablets (Aleve, PMBAY98-7111); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Advanced Solid Tumors
Interventions: Alisertib; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Healthy
Interventions: Mycophenolate Mofetil, CellCept®; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy
Interventions: Zaleplon 10 mg Capsules, SONATA® 10 mg capsules; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Major Depressive Disorder
Interventions: LY03005, Pristiq; Drug
Lead sponsor: Luye Pharma Group Ltd.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: LY3023414 Reference Fasted, LY3023414 Test Fasted, LY3023414 Test Fed; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Prostatic Neoplasms, Genital Neoplasms, Male, Genital Diseases, Male, Prostatic Diseases
Interventions: EPI-506; Drug
Lead sponsor: ESSA Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 4
States / cities: Scottsdale, Arizona • Ann Arbor, Michigan • Detroit, Michigan + 1 more

Conditions: Muscle Hypertrophy, Healthy and Well-Trained Men and Women
Interventions: Time Restricted Eating, Normal Feeding, Resistance Training, Whey Protein; Other · Dietary Supplement
Lead sponsor: California State University, Fullerton; Other
Eligibility: 18 Years to 35 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Fullerton, California

Conditions: Parkinson Disease
Interventions: KM-819, Placebo; Drug
Lead sponsor: FAScinate Therapeutics Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 314 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 3
States / cities: Glendale, California • San Diego, California • Royal Oak, Michigan

Conditions: Healthy
Interventions: Lamotrigine, Lamictal®; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited, India; Industry
Eligibility: 20 Years to 44 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Quadrangle Drive, North Carolina

Conditions: Glucose Metabolism Disorders
Interventions: Weight Loss; Other
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years to 64 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Healthy
Interventions: metformin HC1 750 mg extended-release tablets; Drug
Lead sponsor: Ranbaxy Laboratories Limited; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Type 1 Diabetes Mellitus
Interventions: Insulin glargine, 300 units per milliliter (U/mL), Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 3
States / cities: West Des Moines, Iowa • Houston, Texas • Bridgeport, West Virginia

Conditions: Healthy
Interventions: Seltorexant 40 mg, Seltorexant 20 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Weight Loss, Gut Microbiome, Anti-Aging
Interventions: P-IF, HH; Behavioral
Lead sponsor: Skidmore College; Other
Eligibility: 25 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Saratoga Springs, New York

Conditions: Healthy
Interventions: Leptin administration, Fasting; Drug · Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2003
U.S. locations: 2
States / cities: Boston, Massachusetts • Cambridge, Massachusetts

Conditions: Healthy
Interventions: Cilostazol Tablets 100 mg, Pletal® Tablets 100 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Cushing's Disease, Cushing Syndrome, Cushing Disease
Interventions: Cushing's QoL (Quality of Life Questionnaire), Nottingham Health Profile (NHP), Hospital Anxiety and Depression Scale (HADS), Perceived Stress Scale (PSS), Barratt's Impulsivity Scale (BIS), Beck Depression Inventory (BDI), State-Trait Anxiety Inventory (STAI), State Food Craving Questionnaire-State (FCQ-S), Trait Food Craving Questionnaire-Trait (FCQ-T), Visual Analogue Scale (VAS), Sensitivity to Reinforcement of Addictive and other Primary Rewards (STRAP-R) food variant; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 14 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Search by objective public record fields.

Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus

Practicality of Intermittent Fasting and Its Effect on Markers of Aging and Oxidative Stress

Pilot Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted Conditions

Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer

VibraCool Device to Reduce Pain and Opioid Use After Anterior Cruciate Ligament Reconstruction (ACLR)

IDegLira HIGH Trial

A Pharmacokinetic Trial of Naproxen Sodium and Diphenhydramine Hydrochloride Soft Capsules Versus Naproxen Sodium and Diphenhydramine Hydrochloride Tablets in Healthy Adult Subjects

Study of MLN8237 in Participants With Advanced Solid Tumors

Mycophenolate Mofetil 250 mg Capsules Under Fasting Conditions

Zaleplon 10 mg Capsules Under Non-Fasting Conditions

A Study of LY03005 vs Pristiq

A Study of LY3023414 Formulations and the Effect of Food

Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer

Time-Restricted Eating and Muscle Hypertrophy

A Study to Evaluate Safety and Efficacy of KM-819 in Healthy Adults and Participants with Parkinson's Disease

Bioequivalence Study for Lamotrigine Tablets 200 mg Under Fasting Condition

Study of Fat Tissue's Ability to Take up Sugar in the Obese Population

Bioequivalence Study of Metformin HCl 750 mg XR Under Fasting Conditions

Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy)

A Study to Evaluate the Relative Oral Bioavailability of Seltorexant (JNJ-42847922) After Administration of 3 Different Formulations in Healthy Participants Under Fasted and Semi-fasted Conditions

Low Sugar Protein Pacing, Intermittent Fasting Diet in Men and Women

Secondary Analysis of Gut Hormones and Inflammatory Cytokines in Fasting Subjects

Fasting Study of Cilostazol Tablets 100 mg and Pletal® Tablets 100 mg

Collecting Information About Treatment Results for Patients With Cushing's Syndrome